RU2014128297A - Комбинация факторов роста, цитокинов, антибактериальных/антивирусных факторов, факторов стволовых клеток, белков комплемента с3а/с4а, иммуноглобулинов и хемотоксических факторов - Google Patents

Комбинация факторов роста, цитокинов, антибактериальных/антивирусных факторов, факторов стволовых клеток, белков комплемента с3а/с4а, иммуноглобулинов и хемотоксических факторов Download PDF

Info

Publication number
RU2014128297A
RU2014128297A RU2014128297A RU2014128297A RU2014128297A RU 2014128297 A RU2014128297 A RU 2014128297A RU 2014128297 A RU2014128297 A RU 2014128297A RU 2014128297 A RU2014128297 A RU 2014128297A RU 2014128297 A RU2014128297 A RU 2014128297A
Authority
RU
Russia
Prior art keywords
factors
combination
colitis
total
combination according
Prior art date
Application number
RU2014128297A
Other languages
English (en)
Other versions
RU2642650C2 (ru
Inventor
Альберто Барторелли
Мария Роза Гобби
Original Assignee
Бионест Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT002445A external-priority patent/ITMI20112445A1/it
Priority claimed from IT002440A external-priority patent/ITMI20112440A1/it
Priority claimed from IT002432A external-priority patent/ITMI20112432A1/it
Priority claimed from IT002433A external-priority patent/ITMI20112433A1/it
Priority claimed from IT002443A external-priority patent/ITMI20112443A1/it
Priority claimed from IT002439A external-priority patent/ITMI20112439A1/it
Priority claimed from IT002435A external-priority patent/ITMI20112435A1/it
Priority claimed from IT002446A external-priority patent/ITMI20112446A1/it
Priority claimed from IT002441A external-priority patent/ITMI20112441A1/it
Application filed by Бионест Лтд. filed Critical Бионест Лтд.
Publication of RU2014128297A publication Critical patent/RU2014128297A/ru
Application granted granted Critical
Publication of RU2642650C2 publication Critical patent/RU2642650C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2053—IL-8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/206—IL-9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

1. Комбинация цитокинов, факторов роста, хемотаксических факторов, факторов стволовых клеток, белков комплемента, иммуноглобулинов и антибактериальных/антивирусных факторов следующего состава:2. Комбинация по п. 1, получаемая путем экстрагирования молозива.3. Комбинация по п. 1, получаемая путем экстрагирования плаценты.4. Комбинация по п. 1, получаемая путем экстрагирования сыворотки, собранной за 5-15 дней до родов.5. Комбинация по пп. 1-4 для применения в лечении заболеваний, требующих восстановления тканей и регенерации и для замещения терапии/трансплантологии с применением стволовых клеток.6. Комбинация по п. 5, которую применяют для лечения заболеваний, являющихся аутоиммунными заболеваниями, невропатическими болями, остеопорозом, раневыми поражениями, ожогами, кожными язвами, повреждениями ротовой полости, некротическим острым колитом, болезнью Крона, гастро-эзофагальным рефлюксом, энтероколитом, вызванным СПИДом, синдромом раздраженной толстой кишки, инфекционным колитом, спастическим колитом, колитом, вызванным приемом антибиотиков, хиатальной грыжей, синдромом короткого пищевода.7. Фармацевтическая композиция, содержащая сочетания по пп. 1-4 в качестве активных ингредиентов в смеси с приемлемыми носителями и/или эксципиентами.8. Фармацевтическая композиция по п. 7 для перорального введения.9. Фармацевтическая композиция по п. 7 для местного введения.

Claims (9)

1. Комбинация цитокинов, факторов роста, хемотаксических факторов, факторов стволовых клеток, белков комплемента, иммуноглобулинов и антибактериальных/антивирусных факторов следующего состава:
Цитокины (пкг/мг)   Значение мин. Значение макс. IL-1a 0.80 2.90 IL-1b 0.02 0.09 IL-2 0.75 5.00 IL-4 0.04 0.17 IL-6 0.10 1.20 IL-8 0.50 2.50 IL-9 0.50 3.60 IL-10 0.50 2.80 IL-12 0.50 2.00 IL-15 1.10 4.30 IL-17 15.00 150.00 INF гамма 3.00 30.00 TNFα 15.00 30.00 IL-1 Ra 10.00 30.00 Итого 47.81 264.56 Факторы роста (пкг/мг)   Значение мин. Значение макс. TGF-β1 150.00 300.00 IGF-1 300.00 800.00 NGF 1.00 10.00 PDGF 5.00 100.00 EGF 4.80 9.40 ВМР2 15.00 50.00 b.FGF 100.00 200.00 FGF-2 5.00 20.00 HGF 40.00 80.00 VEGF 50.00 300.00 Итого 670.80 1869.40
Факторы стволовых клеток (пкг/мг)   Значение мин. Значение макс. G-CSF 10.00 20.00 GM-CSF 100.00 1000.00 LIF 15.00 50.00 SCF 1.00 10.00 SDF-1 10.00 40.00 Итого 136.00 1120.00 Хемотаксические факторы (пкг/мг)   Значение мин. Значение макс. EOTAXIN 1.00 15.00 MCP-1 1.00 5.00 Итого 2.00 20.00 Антибактериальные/антивирусные факторы (мкг/мг) Трансферрин 0.50 1.00 Лактоферрин 0.80 2.50 Лизоцим 10.00 40.00 Лактопероксидаза 10.00 30.00 Итого 21.30 73.5 Белки комплемента (пкг/мг)   Значение мин. Значение макс. C3A 0.20 0.70 C4A 0.90 2.00 Итого 1.10 2.70 Иммуноглобулины (мг/мг)   Значение мин. Значение макс. IgG 0.20 0.50 IgA 0.10 0.20 IgM 0.05 0.15 Итого 0.35 0.85
2. Комбинация по п. 1, получаемая путем экстрагирования молозива.
3. Комбинация по п. 1, получаемая путем экстрагирования плаценты.
4. Комбинация по п. 1, получаемая путем экстрагирования сыворотки, собранной за 5-15 дней до родов.
5. Комбинация по пп. 1-4 для применения в лечении заболеваний, требующих восстановления тканей и регенерации и для замещения терапии/трансплантологии с применением стволовых клеток.
6. Комбинация по п. 5, которую применяют для лечения заболеваний, являющихся аутоиммунными заболеваниями, невропатическими болями, остеопорозом, раневыми поражениями, ожогами, кожными язвами, повреждениями ротовой полости, некротическим острым колитом, болезнью Крона, гастро-эзофагальным рефлюксом, энтероколитом, вызванным СПИДом, синдромом раздраженной толстой кишки, инфекционным колитом, спастическим колитом, колитом, вызванным приемом антибиотиков, хиатальной грыжей, синдромом короткого пищевода.
7. Фармацевтическая композиция, содержащая сочетания по пп. 1-4 в качестве активных ингредиентов в смеси с приемлемыми носителями и/или эксципиентами.
8. Фармацевтическая композиция по п. 7 для перорального введения.
9. Фармацевтическая композиция по п. 7 для местного введения.
RU2014128297A 2011-12-30 2012-12-27 Комбинация факторов роста, цитокинов, антибактериальных/антивирусных факторов, факторов стволовых клеток, белков комплемента с3а/с4а, иммуноглобулинов и хемотаксических факторов RU2642650C2 (ru)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
IT002440A ITMI20112440A1 (it) 2011-12-30 2011-12-30 Formulazioni contenenti citochine, fattori di crescita, chemiotattici, antibatterici ed eventualmente immunoglobuline e complemento, per la terapia topica delle lesioni corneali
ITMI2011A002432 2011-12-30
ITMI2011A002443 2011-12-30
ITMI2011A002441 2011-12-30
IT002432A ITMI20112432A1 (it) 2011-12-30 2011-12-30 Kit per il trattamento e la prevenzione dell'alopecia
IT002433A ITMI20112433A1 (it) 2011-12-30 2011-12-30 Composizioni per la terapia orale adiuvante dell'anoressia comprendenti anticorpi, antibatterici, fattori di crescita e citochine
ITMI2011A002445 2011-12-30
IT002443A ITMI20112443A1 (it) 2011-12-30 2011-12-30 Composizioni orali per la terapia dell'osteoporosi comprendenti fattori di crescita, citochine antibatterici e anticorpi
ITMI2011A002440 2011-12-30
IT002439A ITMI20112439A1 (it) 2011-12-30 2011-12-30 Composizioni per la terapia del dolore neuropatico per via orale comprendenti citochine, fattori di crescita, rna, antibatterici e anticorpi
ITMI2011A002435 2011-12-30
IT002445A ITMI20112445A1 (it) 2011-12-30 2011-12-30 Uso di citochine, fattori di crescita, fattori antibatterici e anticorpi, per la terapia topica di ulcere, piaghe e ustioni cutanee
ITMI2011A002446 2011-12-30
ITMI2011A002439 2011-12-30
IT002435A ITMI20112435A1 (it) 2011-12-30 2011-12-30 Profilassi e terapia delle malattie autoimmuni con citochine e fattori di crescita, antibatterici e anticorpi, isolati dai tessuti e dai liquidi biologici dei mammiferi
IT002446A ITMI20112446A1 (it) 2011-12-30 2011-12-30 Composizione per la terapia delle lesioni della mucosa orale
IT002441A ITMI20112441A1 (it) 2011-12-30 2011-12-30 Composizioni comprendenti fattori di crescita, fattori chemiotattici e antibatterici/antivirali, immunoglobuline e citochine per la terapia della enterocolite acuta necrotizzante (nec) nei prematuri e nei neonati a termine e per la prevenzione delle
ITMI2011A002433 2011-12-30
PCT/EP2012/076962 WO2013098333A1 (en) 2011-12-30 2012-12-27 Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins c3a/c4a, immunoglobulins and chemotactic factors

Publications (2)

Publication Number Publication Date
RU2014128297A true RU2014128297A (ru) 2016-02-20
RU2642650C2 RU2642650C2 (ru) 2018-01-25

Family

ID=47598771

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014128297A RU2642650C2 (ru) 2011-12-30 2012-12-27 Комбинация факторов роста, цитокинов, антибактериальных/антивирусных факторов, факторов стволовых клеток, белков комплемента с3а/с4а, иммуноглобулинов и хемотаксических факторов

Country Status (7)

Country Link
US (2) US9555084B2 (ru)
EP (1) EP2797609B1 (ru)
JP (1) JP6139562B2 (ru)
DK (1) DK2797609T3 (ru)
ES (1) ES2609352T3 (ru)
RU (1) RU2642650C2 (ru)
WO (1) WO2013098333A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492512B2 (en) 2011-12-30 2016-11-15 Innomed S.A. Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins C3A/C4A, and chemotactic factors
US10517931B2 (en) * 2013-01-17 2019-12-31 Mimedx Group, Inc. Non-surgical, localized delivery of compositions for placental growth factors
ITUB20160137A1 (it) * 2016-02-04 2017-08-04 Innomed S A Processo di estrazione da colostro
US10933097B1 (en) 2020-03-05 2021-03-02 King Saud University Method of treating a bacterial infection using colostrum
KR20210114646A (ko) * 2020-03-11 2021-09-24 (주)메디코스바이오텍 성장인자를 함유하는 탈모 치료 또는 모발 성장 촉진용 조성물
EP3936110B1 (en) * 2020-07-07 2022-08-31 Dr. Kurt Wolff GmbH & Co. KG Treatment of seasonal hair thinning

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2460135A1 (fr) * 1979-07-02 1981-01-23 Liotet Serge Composition a usage externe a base de colostrum
FR2487676A1 (fr) 1980-07-29 1982-02-05 Oraa Ste Civile Procede d'obtention d'extrait sec de colostrum
FR2627386A1 (fr) * 1988-02-22 1989-08-25 Serge Liotet Composition a usage externe destinee a l'administration oculaire
FR2628973B1 (fr) * 1988-03-25 1990-11-16 Gattefosse Ets Sa Composition cosmetique ou pharmaceutique a usage cutane, et procede pour la preparation d'une telle composition
JPH08503198A (ja) 1992-11-03 1996-04-09 クリエイティブ バイオモレキュルズ，インコーポレイテッド Ｏｐ−３誘導形態形成
US5750149A (en) 1993-01-26 1998-05-12 Horse Vitality Ltd Pharmaceutical and dermocosmetic compositions containing equine colostrum
DE69431300T2 (de) 1993-06-23 2003-07-31 Novatreat Oy Turku Eine pharmazeutische oder kosmetische zubereitung, die eine kolostrumfraktion enthält und deren medizinische verwendung
ATE227557T1 (de) 1995-04-28 2002-11-15 Sara Lee De Nv Verwendung von zahnpflegemitteln enthaltend bovines kolostrum
DE69726285T2 (de) 1996-08-30 2004-09-09 Upfront Chromatography A/S, Kopenhagen Isolierung von immunglobulinen
PL185442B1 (pl) 1996-10-03 2003-05-30 Georgiades Biotech Ltd Środek farmaceutyczny o działaniu immunologicznym i psychotropowym, jego postać terapeutyczna oraz zastosowanie
IT1290347B1 (it) 1997-02-18 1998-10-22 Horse Vitality Ltd Formulazioni farmaceutiche contenenti colostro e uso del colostro per il trattamento della caduta dei capelli
IT1291340B1 (it) 1997-05-09 1999-01-07 Vander Way Limited Formulazioni farmaceutiche contenenti colostro e uso del colostro per il trattamento di affezioni del cavo orale
DE69930746T2 (de) 1998-06-10 2007-03-15 Crum, Albert B. Vorbeugender und therapeutischer nahrungsmittelzusatz zur schaffung/erhaltung einer die gesundheit schützenden darmmikroflora und zur stärkung des immunsystems
JP2000159687A (ja) 1998-11-24 2000-06-13 Snow Brand Milk Prod Co Ltd 非有益腸内微生物定着阻止剤
EP1789073A4 (en) * 2004-09-14 2011-06-08 Nexcell Biosciences Inc ISOLATION OF GROWTH AND DIFFERENTIATION FACTORS FROM COLOSTRUM
WO2006029494A1 (en) 2004-09-14 2006-03-23 Nexcell Biosciences Inc. Extraction of growth and differentiating factors from colostrum
ITMI20051231A1 (it) 2005-06-29 2006-12-30 Pharmaproducts Uk Ltd Formulazioni farmaceutiche contenenti colostro e calcio folinato per il trattamento delle affezioni del cavo orale
CA2649234C (en) 2006-05-04 2015-07-14 Pierluigi Reschiglian Method and device to fractionate stem cells
CN101528253A (zh) * 2006-07-03 2009-09-09 让-保罗·佩罗丹 抗菌剂组合物及其用途
BRPI0721321A2 (pt) 2007-02-20 2013-01-08 Nutricia Nv uso de colostro, e, composiÇço
WO2009046168A1 (en) * 2007-10-02 2009-04-09 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
ITMI20092069A1 (it) * 2009-11-25 2011-05-26 Biofer Spa Metodo per ottenere una miscela di fattori biologici isolati da colostro e miscela di fattori biologici attivi derivata da colostro.
NL2004099C2 (en) 2010-01-15 2011-07-18 Friesland Brands Bv Milk derived antigen specific antibodies for inducing an adaptive immune response, methods of preparation and uses thereof.
IT1405998B1 (it) 2010-12-09 2014-02-06 Bionest Ltd Gel polifunzionale contro la secchezza vaginale ad effetto diretto e ritardato
US9492512B2 (en) 2011-12-30 2016-11-15 Innomed S.A. Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins C3A/C4A, and chemotactic factors

Also Published As

Publication number Publication date
US20140369957A1 (en) 2014-12-18
ES2609352T3 (es) 2017-04-19
JP6139562B2 (ja) 2017-05-31
US10098927B2 (en) 2018-10-16
EP2797609A1 (en) 2014-11-05
US20170087213A1 (en) 2017-03-30
US9555084B2 (en) 2017-01-31
RU2642650C2 (ru) 2018-01-25
JP2015506932A (ja) 2015-03-05
DK2797609T3 (en) 2017-01-09
WO2013098333A1 (en) 2013-07-04
EP2797609B1 (en) 2016-10-05

Similar Documents

Publication Publication Date Title
RU2014128297A (ru) Комбинация факторов роста, цитокинов, антибактериальных/антивирусных факторов, факторов стволовых клеток, белков комплемента с3а/с4а, иммуноглобулинов и хемотоксических факторов
Bennett et al. First‐trimester human chorionic villi express both immunoregulatory and inflammatory cytokines: a role for interleukin‐10 in regulating the cytokine network of pregnancy
US20160340651A1 (en) Methods for culturing dermal cells for treatment of skin injuries such as burns
Meier et al. Emerging new drugs for wound repair
RU2009126728A (ru) Лечение молодых свиней с помощью антигена pcv2
CN106754639B (zh) 一种间充质干细胞因子大规模制备方法
MX2023010939A (es) Metodos y composiciones de muteinas de il2 sesgadas.
Teramatsu et al. Expression and effects of epidermal growth factor on human periodontal ligament cells
Julianto et al. Topical delivery of mesenchymal stem cells “secretomes” in wound repair
Dames et al. Immunomodulatory treatment with systemic GM-CSF augments pulmonary immune responses and improves neurological outcome after experimental stroke
Cai et al. Transforming growth factor-β1-overexpressing mesenchymal stromal cells induced local tolerance in rat renal ischemia/reperfusion injury
CN111904980B (zh) 间充质干细胞与在治疗急性肺损伤、急性呼吸窘迫症或肺纤维化中的用途
Jungraithmayr The putative role of mast cells in lung transplantation
JP4846598B2 (ja) 弱毒化ウサギ粘液腫ウイルスに基づくモノ非特異的免疫誘導剤
CL2023001650A1 (es) Tratamiento de la enfermedad de danon
JP2007534664A5 (ru)
Canciello et al. Progesterone prolongs viability and anti-inflammatory functions of explanted preterm ovine amniotic membrane
Gupta et al. Placental tissues-from reproductive to regenerative biology
BR112022022355A2 (pt) Composição, uso de uma composição, e, métodos para tratamento de uma doença, distúrbio ou trauma do sistema respiratório, para tratamento ou promoção de um transplante de um órgão ou tecido do trato respiratório, para prevenir coágulo sanguíneo, para promover estabilidade hemodinâmica, para reduzir a necessidade de suporte inotrópico, para melhorar a capacidade de oxigenação, para prevenir o dano de tecido, para reverter o dano ao tecido, para reduzir contagens de neutrófilo, para aumentar as contagens de linfócito, para diminuir citocinas pró-inflamatórias e para aumentar interferon-alfa
Ustymenko et al. The clinical effectiveness of cryopreserved human amniotic membrane in diabetic foot syndrome
RU2018135044A (ru) Бесклеточные терапевтические средства для регенеративной медицины и способы их получения
US20180280434A1 (en) Sequential application of macrophages for wound healing
Wang et al. Experimental research on bletilla carrying exogenous basic fibroblast growth factor that promotes wound healing
US20230040943A1 (en) Medicament comprising a combination of amniotic membrane and umbilical cord blood serum for wound healing
Arief et al. Amnion membrane properties and functions in dentistry

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant